^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

thiotepa

i
Other names: DSP-1958
Company:
Generic mfg.
Drug class:
DNA synthesis inhibitor, Alkylating agent
Related drugs:
Phase 2
Fred Hutchinson Cancer Center
Not yet recruiting
Last update posted :
02/19/2024
Initiation :
03/15/2024
Primary completion :
10/31/2024
Completion :
10/31/2025
KMT2A • HLA-DRB1 • HLA-B
|
MLL rearrangement • MLL rearrangement
|
cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion
Phase 1/2
ExCellThera inc.
Recruiting
Last update posted :
02/19/2024
Initiation :
12/01/2021
Primary completion :
06/01/2026
Completion :
06/01/2026
HLA-DRB1 • CD34
|
cyclophosphamide • clofarabine • fludarabine IV • thiotepa • busulfan • ECT-001-CB
Phase 1
Stanford University
Recruiting
Last update posted :
02/19/2024
Initiation :
09/07/2021
Primary completion :
12/01/2025
Completion :
12/01/2025
HLA-DRB1 • HLA-B • HLA-C
|
Jakafi (ruxolitinib) • cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim) • plerixafor
Phase 2
Fred Hutchinson Cancer Center
Recruiting
Last update posted :
02/15/2024
Initiation :
05/10/2022
Primary completion :
10/08/2024
Completion :
06/30/2026
HLA-DRB1 • CD34 • HLA-B
|
cyclophosphamide • fludarabine IV • thiotepa • Omisirge (omidubicel) • dilanubicel (NLA101)
Phase 2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
02/09/2024
Initiation :
10/21/2021
Primary completion :
12/31/2024
Completion :
12/31/2024
KRAS • NRAS • DNMT3A • NF1 • RUNX1 • ASXL1 • PTPN1
|
TP53 mutation • KRAS mutation • NRAS mutation • RAS mutation
|
Venclexta (venetoclax) • cladribine • fludarabine IV • thiotepa • busulfan
Phase 2
Fred Hutchinson Cancer Center
Active, not recruiting
Last update posted :
02/08/2024
Initiation :
02/03/2015
Primary completion :
04/01/2025
Completion :
04/01/2025
HLA-DRB1 • HLA-B • HLA-C
|
cyclophosphamide • methotrexate • fludarabine IV • thiotepa
Phase 2
Fred Hutchinson Cancer Center
Recruiting
Last update posted :
02/05/2024
Initiation :
05/05/2021
Primary completion :
07/01/2027
Completion :
07/01/2027
HLA-DRB1 • CD34 • HLA-DQB1 • HLA-B • HLA-C
|
fludarabine IV • thiotepa • busulfan • Ovastat (treosulfan)
Phase 3
Children's Oncology Group
Active, not recruiting
Last update posted :
01/22/2024
Initiation :
05/14/2018
Primary completion :
09/30/2026
Completion :
09/30/2026
MYCN
|
MYCN amplification
|
cisplatin • Xalkori (crizotinib) • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane
Phase 2
Children's Oncology Group
Recruiting
Last update posted :
01/22/2024
Initiation :
07/13/2021
Primary completion :
12/21/2029
Completion :
12/21/2029
NF1
|
AFP elevation
|
carboplatin • cyclophosphamide • ifosfamide • etoposide IV • thiotepa • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez)
Phase 3
Children's Oncology Group
Recruiting
Last update posted :
01/22/2024
Initiation :
03/15/2023
Primary completion :
12/01/2027
Completion :
12/01/2027
FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C
|
FLT3-ITD mutation
|
Rituxan (rituximab) • cyclophosphamide • methotrexate • melphalan • fludarabine IV • thiotepa • busulfan • Mabtas (rituximab biosimilar)
Phase 2
St. Jude Children's Research Hospital
Active, not recruiting
Last update posted :
01/19/2024
Initiation :
01/31/2019
Primary completion :
07/01/2024
Completion :
07/01/2025
FLT3 • RUNX1 • KMT2A • ETV6 • WT1 • CREBBP • NUP98 • NSD1 • HOXA9 • NUP214 • CBFA2T3 • GLIS2 • KAT6A • KDM5A • DEK • AFDN • MLLT10
|
FLT3-ITD mutation • WT1 mutation • MLL fusion • NUP98-NSD1 fusion
|
cyclophosphamide • Blincyto (blinatumomab) • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim)
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
01/15/2024
Initiation :
04/30/2021
Primary completion :
04/01/2025
Completion :
04/01/2025
TP53 • HLA-DRB1 • CD34 • CD4
|
TP53 mutation
|
cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan
Phase 2
Fred Hutchinson Cancer Center
Recruiting
Last update posted :
01/11/2024
Initiation :
11/19/2019
Primary completion :
12/31/2026
Completion :
12/31/2028
HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
|
cyclophosphamide • sirolimus • fludarabine IV • thiotepa • busulfan
Phase 2
Fred Hutchinson Cancer Center
Active, not recruiting
Last update posted :
01/05/2024
Initiation :
11/18/2005
Primary completion :
12/22/2023
Completion :
12/22/2024
HLA-DRB1 • HLA-B
|
cyclophosphamide • fludarabine IV • thiotepa
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
01/05/2024
Initiation :
12/01/2012
Primary completion :
12/01/2024
Completion :
12/01/2024
CD34 • CD4
|
Chr t(15;17)
|
cyclophosphamide • Firmagon (degarelix) • thiotepa • leuprolide acetate for depot suspension • Kepivance (palifermin)
Phase 1
Dana-Farber Cancer Institute
Recruiting
Last update posted :
01/04/2024
Initiation :
01/12/2021
Primary completion :
10/31/2025
Completion :
10/31/2027
TP53 • HLA-DRB1
|
TP53 mutation
|
cyclophosphamide • fludarabine IV • thiotepa
Phase 2
Randy Windreich
Completed
Last update posted :
12/19/2023
Initiation :
09/04/2015
Primary completion :
04/12/2023
Completion :
04/12/2023
FLT3 • CD34
|
FLT3 positive
|
Campath (alemtuzumab) • melphalan • fludarabine IV • hydroxyurea • thiotepa • busulfan
Phase 3
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
12/15/2023
Initiation :
02/14/2024
Primary completion :
12/31/2029
Completion :
12/31/2029
ALK • TERT • MYCN
|
cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane
Phase 2
Case Comprehensive Cancer Center
Active, not recruiting
Last update posted :
12/11/2023
Initiation :
03/21/2018
Primary completion :
06/09/2024
Completion :
06/09/2025
FLT3
|
FLT3 mutation
|
melphalan • fludarabine IV • thiotepa • Kepivance (palifermin) • captisol-enabled melphalan
Phase 2
Baptist Health South Florida
Not yet recruiting
Last update posted :
12/08/2023
Initiation :
03/01/2024
Primary completion :
03/01/2031
Completion :
03/01/2031
CD34
|
cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan
Phase N/A
Shanghai General Hospital, Shanghai Jiao Tong U...
Not yet recruiting
Last update posted :
11/28/2023
Initiation :
01/01/2024
Primary completion :
01/01/2026
Completion :
01/01/2027
HLA-DRB1 • HLA-B • HLA-C
|
cytarabine • fludarabine IV • thiotepa • busulfan
Phase 2
Sheba Medical Center
Active, not recruiting
Last update posted :
11/28/2023
Initiation :
10/09/2018
Primary completion :
04/01/2024
Completion :
04/01/2024
CD34
|
cytarabine • etoposide IV • melphalan • thiotepa
Phase N/A
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
11/21/2023
Initiation :
08/23/2016
Primary completion :
11/20/2023
Completion :
11/20/2023
TP53 • FLT3 • ABL1 • BCR • RUNX1 • ASXL1 • CRLF2 • IKZF1
|
TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • IKZF1 mutation • MLL mutation
|
cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim)
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
11/15/2023
Initiation :
08/19/2020
Primary completion :
05/09/2025
Completion :
05/09/2025
HLA-DRB1 • HLA-B • HLA-C
|
etoposide IV • melphalan • fludarabine IV • thiotepa • cyclosporin A microemulsion
Phase 1
M.D. Anderson Cancer Center
Withdrawn
Last update posted :
10/04/2023
Initiation :
01/14/2021
Primary completion :
12/20/2022
Completion :
12/20/2022
HLA-DRB1 • HLA-B • HLA-C • KIR2DS2
|
etoposide IV • melphalan • fludarabine IV • thiotepa
Phase 2
Masonic Cancer Center, University of Minnesota
Recruiting
Last update posted :
10/03/2023
Initiation :
06/01/2016
Primary completion :
07/01/2024
Completion :
07/01/2025
CD34
|
carboplatin • cyclophosphamide • etoposide IV • melphalan • thiotepa
Phase 3
Children's Oncology Group
Active, not recruiting
Last update posted :
09/25/2023
Initiation :
08/06/2007
Primary completion :
12/31/2016
Completion :
12/31/2028
IGF1
|
cisplatin • carboplatin • cyclophosphamide • etoposide IV • methotrexate • vincristine • leucovorin calcium • thiotepa • Neupogen (filgrastim)
Phase 2
Fred Hutchinson Cancer Center
Recruiting
Last update posted :
09/11/2023
Initiation :
08/29/2019
Primary completion :
12/31/2024
Completion :
12/31/2024
HLA-DRB1 • HLA-B • HLA-C
|
cyclophosphamide • methotrexate • fludarabine IV • thiotepa • busulfan
Phase 2
Fred Hutchinson Cancer Center
Completed
Last update posted :
08/30/2023
Initiation :
12/17/2013
Primary completion :
01/30/2023
Completion :
07/30/2023
HLA-DRB1 • HLA-B • HLA-C
|
methotrexate • fludarabine IV • thiotepa
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
08/22/2023
Initiation :
07/25/2018
Primary completion :
07/01/2024
Completion :
07/01/2024
TP53 • ABL1 • BCR • RUNX1 • KMT2A • CRLF2 • IKZF1 • NUP214 • CDKN1A • DEK
|
TP53 mutation • RUNX1 mutation • KMT2A rearrangement • IKZF1 mutation • MLL mutation • Chr t(9;11)
|
Rituxan (rituximab) • cyclophosphamide • clofarabine • melphalan • fludarabine IV • thiotepa • busulfan
Phase N/A
Masonic Cancer Center, University of Minnesota
Recruiting
Last update posted :
04/05/2023
Initiation :
10/20/2011
Primary completion :
03/01/2024
Completion :
03/01/2025
MYCN • CD34
|
LDH elevation • MYCN amplification • MYCN expression
|
cisplatin • carboplatin • paclitaxel • ifosfamide • etoposide IV • melphalan • thiotepa • busulfan
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
03/14/2023
Initiation :
01/14/2019
Primary completion :
12/31/2021
Completion :
12/31/2023
MYCN
|
MYCN amplification
|
cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Unituxin (dinutuximab) • Leukine (sargramostim) • dexrazoxane
Phase 2
Stanford University
Suspended
Last update posted :
03/13/2023
Initiation :
02/27/2020
Primary completion :
02/01/2025
Completion :
02/01/2026
HLA-DRB1
|
cyclophosphamide • fludarabine IV • thiotepa • busulfan
Phase 3
Gustave Roussy, Cancer Campus, Grand Paris
Recruiting
Last update posted :
02/13/2023
Initiation :
11/05/2019
Primary completion :
11/01/2026
Completion :
11/01/2032
MYCN • MYCL
|
MYCN amplification • MYCL amplification
|
cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • dacarbazine • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • cyclophosphamide intravenous • vindesine
Phase 2
Sidney Kimmel Cancer Center at Thomas Jefferson...
Completed
Last update posted :
01/06/2023
Initiation :
12/24/2012
Primary completion :
04/15/2022
Completion :
12/05/2022
TP53 • FLT3
|
TP53 deletion • Chr del(5q) • Chr del(7q)
|
cyclophosphamide • fludarabine IV • thiotepa • busulfan
Phase 1/2
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
12/26/2022
Initiation :
11/20/2006
Primary completion :
06/18/2021
Completion :
06/18/2021
HLA-DRB1 • HLA-B • HLA-C
|
clofarabine • melphalan • thiotepa • Neupogen (filgrastim)
Phase 2
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
12/08/2022
Initiation :
08/12/2008
Primary completion :
10/15/2021
Completion :
10/15/2021
KMT2A
|
MLL rearrangement • MLL rearrangement
|
cyclophosphamide • fludarabine IV • thiotepa
Phase 3
The Netherlands Cancer Institute
Active, not recruiting
Last update posted :
10/12/2022
Initiation :
09/01/2014
Primary completion :
01/01/2023
Completion :
10/01/2026
HER-2 • ER • BRCA1 • BRCA2
|
BRCA2 mutation • BRCA1 mutation • HER-2 negative
|
carboplatin • gemcitabine • paclitaxel • docetaxel • doxorubicin hydrochloride • cyclophosphamide • thiotepa
Phase 2/3
The Netherlands Cancer Institute
Active, not recruiting
Last update posted :
10/12/2022
Initiation :
01/01/2010
Primary completion :
06/01/2023
Completion :
12/01/2029
HER-2 • ER • PGR
|
HER-2 negative • ER negative
|
carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • thiotepa
Phase 2
Baptist Health South Florida
Withdrawn
Last update posted :
09/27/2022
Initiation :
09/01/2022
Primary completion :
03/01/2030
Completion :
03/01/2030
CD34
|
cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan
Phase 2
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
08/05/2022
Initiation :
05/03/2010
Primary completion :
03/30/2021
Completion :
03/30/2021
CD34
|
Chr t(4;14) • Chr t(14;16) • Chr t(15;17)
|
cyclophosphamide • clofarabine • melphalan • fludarabine IV • thiotepa • busulfan